MedTrace Logo

Phototherapy Combination With Topicals in Vitiligo

NCT04440371 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-09-13

No results posted yet for this study

Summary

Patients will be included in a randomized controlled clinical trial, will enroll only adult vitiligo patients with surface area of at least 10% who are being followed in the outpatient dermatology clinics of King Abdullah University Hospital (KAUH) and are planned to start on phototherapy Narrow Band Ultraviolet light B (NBUVB), regardless if they have previous treatment for their disease, one month wash off period will be given for patients who are already on phototherapy or other treatments for vitiligo.

Conditions

  • Vitiligo, Generalized

Interventions

COMBINATION_PRODUCT

Tacrolimus 0.1% ointment twice daily plus NBUVB 3 times weekly

Tacrolimus ointment plus phototherapy NBUVB (Tacrolimus arm)

COMBINATION_PRODUCT

Calcipotriol/Betamethasone ointment plus NBUVB

Calcipotriol/Betamethasone ointment once daily plus NBUVB 3 times weekly

Sponsors & Collaborators

  • Jordan University of Science and Technology

    lead OTHER

Principal Investigators

  • Diala Alshiyab, MD · Jordan University of Science and Technology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-21
Primary Completion
2023-07-30
Completion
2023-12-30

Countries

  • Jordan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04440371 on ClinicalTrials.gov